Email Us
View Reports

Companion Diagnostic Market

Companion Diagnostic Market - By Technology (Immunohistochemistry, Polymerase Chain Reaction, In situ Hybridization, Real-Time PCR, Gene Sequencing), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Lekemia, Melanoma), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Size, Share, Growth and Global Forecast to 2024

  • ID : 85297949  |  
  • Published : Feb-2019  |  
  • Region : Global  |  
  • Pages : 165   |  
  • Publisher : Mordor Intelligence

Companion Diagnostic Market Size and Growth Rate:

According to the Research Report, the Global Companion Diagnostic Market Size was Expected to Reach USD 6.5 Billion by 2024 during the forecast period 2019-2024.

Companion Diagnostic Market Growth Drivers and Restraints:

The growth of the global companion diagnostic market can be attributed to the rising focus on personalized medicine and co-development of drug and diagnostic technologies. In addition, rising cases of adverse drug reactions related to drugs, due to the lack of efficacy, drive the need for companion diagnostics. One of the major factors driving the growth of the companion diagnostic market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics to focus on cost regulations, there has been a significant number of opportunities of its applications in indications like cancer, cardiovascular and neurological disorders etc.

The Scope of the Companion Diagnostic Market Report:

Companion diagnostic test provides information that is essential for the safe and effective use of a corresponding drug or biological product. As per the scope of the report, the market studied has been segmented by technology type, indications, and geography. By technology type, the market studied has been further segmented into immunohistochemistry, polymerase chain reaction, in-situ hybridization, real time-polymerase chain reaction, gene sequencing, and other technologies.

Companion Diagnostic Market Regional Presence:

North America dominated the overall Companion Diagnostics Market with the United States accounting for the major contributor to the market. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, and it is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostics assays are classified as IVD class III products, which represents the high-risk category, and consequently the highest level of regulatory control. Hence, owing to high healthcare technology adoption rates, and increasing demand for personalized medicine the market of companion diagnostics in the United States, is expected to register a substantial growth rate during the forecast period.

Some of the Promising Companies dominating the  Global Companion Diagnostic Market Profiled in the Report are:

  • Abbott
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • Biomerieux SA
  • Qiagen NV

Global Companion Diagnostic Market - By Technology:

  • Immunohistochemistry (IHC)
  • Polymerase Chain Reaction (PCR)
  • In situ Hybridization (ISH)
  • Real-Time PCR (RT-PCR)
  • Gene Sequencing
  • Other Technologies

Global Companion Diagnostic Market - By Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma

Global Companion Diagnostic Market - By Region:

  • North America
  • Europe
  • Asia-pacific
  • Latin America
  • Middle East & Africa

Key Market Trends for this Global Companion Diagnostic Market:

In-Situ Hybridization (ISH) Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

In-situ hybridization (ISH), especially fluorescence in-situ hybridization (FISH) is a reliable, reproducible, sensitive, and accurate procedure, which is less affected by tissue fixation and analytical variables, in comparison to immunochemistry and other techniques. It offers the benefit of simultaneous evaluation of morphology and gene amplification. FISH has been the method of choice for use in companion diagnostic for several cancer therapies, such as trastuzumab, lapatinib, and crizotinib, that have been already approved by FDA and other therapies, like everolimus, ridaforolimus, bicalutamide, TBD, and other drugs, that are yet to obtain regulatory approval.

The global market for in-situ hybridization in CDx is growing because of technological advancements, like the recent development of bright-field in-situ hybridization techniques, chromogenic in-situ hybridization (CISH) and the automated silver-enhanced in-situ hybridization (SISH) for the determination of gene status. Thus, considering the aforementioned factors, the ISH segment is expected to exhibit growth over the forecast period.

1. INTRODUCTION

1. Study Deliverables

2. Study Assumptions

3. Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

1. Market Overview

2. Market Drivers

1. Companies Promoting Personalized Medicine and Targeted Therapy as a New Treatment Option

2. Increasing Cases of Adverse Drug Reactions

3. Co-Development of Drug and Diagnostic Technology

3. Market Restraints

1. High Cost of Drug Development and Associated Clinical Trials

2. Reimbursement Issues among Many Countries

4. Industry Attractiveness Porter's Five Force Analysis

1. Threat of New Entrants

2. Bargaining Power of Buyers/Consumers

3. Bargaining Power of Suppliers

4. Threat of Substitute Products

5. Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

1. By Technology

1. Immunohistochemistry (IHC)

2. Polymerase Chain Reaction (PCR)

3. In situ Hybridization (ISH)

4. Real-Time PCR (RT-PCR)

5. Gene Sequencing

6. Other Technologies

2. By Indication

1. Lung Cancer

2. Breast Cancer

3. Colorectal Cancer

4. Leukemia

5. Melanoma

6. Other Indications

3. Geography

1. North America

1. United States

2. Canada

3. Mexico

2. Europe

1. United Kingdom

2. Germany

3. France

4. Italy

5. Spain

6. Rest of Europe

3. Asia-Pacific

1. China

2. Japan

3. India

4. Australia

5. South Korea

6. Rest of Asia Pacific

4. Middle East & Africa

1. GCC

2. South Africa

3. Rest of Middle East & Africa

5. South America

1. Brazil

2. Argentina

3. Rest of South America

6. COMPETITIVE LANDSCAPE

1. Company Profiles

1. Abbott

2. Agilent Technologies, Inc.

3. F. Hoffmann-La Roche Ltd

4. Biomerieux SA

5. Qiagen NV

6. Siemens Healthcare

7. Thermo Fisher Scientific Inc.

8. Danaher Corporation (Beckman Coulter Inc.)

*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?